# A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

> **NCT02078609** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- AML and High Risk MDS

## Interventions

- **DRUG:** LGH447
- **DRUG:** LGH447 + midostaurin

## Key facts

- **NCT ID:** NCT02078609
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-20
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-04-18
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02078609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02078609, "A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02078609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*